arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2401.04863stat.ME
收藏

临床试验中的估计目标与累积发病函数回归:关于可解释性与稳健性的一些新结果

Estimands and cumulative incidence function regression in clinical trials: some new results on interpretability and robustness

Alexandra Bühler, Richard J Cook, Jerald F Lawless

AI总结:

本文基于大样本理论推导了竞争风险下累积发病函数回归模型的治疗效果估计量极限值,揭示了其敏感性,检验了假设检验的拒绝率以建立稳健性,并强调次要分析的重要性。

摘要:

当在涉及竞争风险和半竞争风险的临床试验环境中建模和检验治疗效果时,基于累积发病函数变换的回归分析常被采用。常见的框架包括 Fine-Gray 模型以及基于直接二项回归的模型。我们使用大样本理论推导了当数据根据基于乘积强度的模型生成时,基于此类模型的治疗效果估计量的极限值,并表明该估计目标对多个过程特征敏感。此外,针对不同类型的零假设,还检验了基于累积发病函数回归模型的假设检验的拒绝率,并据此建立了一种稳健性属性。在此类环境中,支持性的治疗效果次要分析对于确保全面理解治疗效果的本质至关重要。为说明此方法,提供了一个针对乳腺癌骨转移患者的姑息治疗研究的应用示例。

英文摘要:

Regression analyses based on transformations of cumulative incidence functions are often adopted when modeling and testing for treatment effects in clinical trial settings involving competing and semi-competing risks. Common frameworks include the Fine-Gray model and models based on direct binomial regression. Using large sample theory we derive the limiting values of treatment effect estimators based on such models when the data are generated according to multiplicative intensity-based models, and show that the estimand is sensitive to several process features. The rejection rates of hypothesis tests based on cumulative incidence function regression models are also examined for null hypotheses of different types, based on which a robustness property is established. In such settings supportive secondary analyses of treatment effects are essential to ensure a full understanding of the nature of treatment effects. An application to a palliative study of individuals with breast cancer metastatic to bone is provided for illustration.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑